1
|
Beg S, Alharbi KS, Alruwaili NK, Alotaibi NH, Almalki WH, Alenezi SK, Altowayan WM, Alshammari MS, Rahman M. Nanotherapeutic systems for delivering cancer vaccines: recent advances. Nanomedicine (Lond) 2020; 15:1527-1537. [PMID: 32410483 DOI: 10.2217/nnm-2020-0046] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
With an increase in the global burden of cancer-related deaths, the quest for developing new therapeutic solutions has taken momentum. In this regard, the idea of using cancer vaccines came to existence approximately 30 years ago, where gene therapy interventions have shown significant improvement in the therapeutic outcomes against several types of cancers. Cancer vaccines usually encounter a number of challenges with limited targeting ability to the tumors. Nanocarriers have been studied as a technological innovation for tumor targeting of gene therapeutics. This article provides a critical insight into the recent progress made in nanotherapeutic strategies for genetic vaccine delivery for treatment against various types of cancers. Moreover, the article intends to provide a summary of the research work being done on this topic.
Collapse
Affiliation(s)
- Sarwar Beg
- Department of Pharmaceutics, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi, India
| | - Khalid S Alharbi
- Department of Pharmacology, College of Pharmacy, Jouf University, Sakakah, Saudi Arabia
| | - Nabil K Alruwaili
- Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakakah, Saudi Arabia
| | - Nasser Hadal Alotaibi
- Department of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakakah, Saudi Arabia
| | - Waleed H Almalki
- Department of Pharmacology & Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia
| | - Sattam K Alenezi
- Department of Pharmacology & Toxicology, Unaizah College of Pharmacy, Qassim University, Qassim, Saudi Arabia
| | - Waleed M Altowayan
- Department of Pharmacy Practice, College of Pharmacy, Qassim University, Qassim, Saudi Arabia
| | - Mohammed S Alshammari
- Department of Pharmacy Practice, Unaizah College of Pharmacy, Qassim University, Qassim, Saudi Arabia
| | - Mahfoozur Rahman
- Department of Pharmaceutical Sciences, SIHAS, Faculty of Health Science, Sam Higginbottom University of Agriculture, Technology & Sciences, Allahabad, India
| |
Collapse
|
2
|
Vaccine adjuvants: smart components to boost the immune system. Arch Pharm Res 2017; 40:1238-1248. [PMID: 29027637 DOI: 10.1007/s12272-017-0969-z] [Citation(s) in RCA: 97] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2017] [Accepted: 09/26/2017] [Indexed: 02/07/2023]
Abstract
Vaccination is an effective approach to prevent the consequences of infectious diseases. Vaccines strengthen immunity and make individuals resistant to infections with pathogens. Although conventional vaccines are highly immunogenic, they are associated with some safety issues. Subunit vaccines are safe, but they require adjuvants to stimulate the immune system because of their weaker immunogenicity. Adjuvants are entities incorporated into vaccines to increase the immunogenic responses of antigens. They play a crucial role in increasing the potency and efficacy of vaccines. Different adjuvants have different modes of action; therefore, a better understanding of their immunology could provide guidance for the development of novel adjuvants. Numerous studies have been conducted using different types of adjuvants to characterize their potency and safety; however, in practice, only few are used in human or animal vaccines. This review aims to introduce the different modes of action of adjuvants and give insight into the types of adjuvants that possess the greatest potential for adjuvanticity.
Collapse
|
3
|
Abstract
The mucosal surfaces represent the major site of entry of many pathogens, and major challenges in vaccine development include safety and stability in a suitable dosage form. Micro- and nanocarrier-based delivery systems as nasal vaccines induce humoral, cellular, and mucosal immunity. The nasal route of vaccination could also offer immunity at several distant mucosal sites (oral, rectal, vaginal, and pulmonary), which is considered a simplified and cost-effective mode of vaccination with enhanced patient compliance. Most of the nasal vaccine delivery systems in the form of microparticulates, nanoparticulates, and liposomes are currently under development and prove to offer immunity in animal models. The importance and potential of the nasal route of administration for vaccines is unexplored, and this chapter outlines the opportunities, challenges, and potential delivery solutions to facilitate the development of improved nasal vaccines for infectious diseases.
Collapse
|
4
|
Spohn G, Bachmann MF. Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines 2014; 7:43-54. [DOI: 10.1586/14760584.7.1.43] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|
5
|
Giri PK, Khuller GK. Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev Vaccines 2014; 7:1341-56. [DOI: 10.1586/14760584.7.9.1341] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
6
|
Lee SH, Lillehoj HS, Jang SI, Lee KW, Kim DK, Lillehoj EP, Yancey RJ, Dominowski PJ. Evaluation of novel adjuvant Eimeria profilin complex on intestinal host immune responses against live E. acervulina challenge infection. Avian Dis 2012; 56:402-5. [PMID: 22856201 DOI: 10.1637/9906-082411-resnote.1] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The effects against avian coccidiosis of two novel adjuvants, Quil A/cholesterol/dimethyl dioctadecyl ammonium bromide/Carbopol (QCDC) and QCDC/Bay R1005 (R)/cytosine-phosphate-guanosine (CpG) oligodeoxynucleotides (CpG ODN [T]) (QCDCRT) emulsified with profilin, a conserved Eimeria recombinant protein, were determined in broiler chickens. Chickens were subcutaneously immunized with isotonic saline (control group), profilin (P), profilin emulsified with QCDC (P-Q), or profilin with QCDCRT (P-QR) at 2 and 9 days post-hatch and orally challenged with 1.0 x 10(4) sporulated oocysts of Eimeria acervulina (EA) at 7 days postimmunization. All profilin-immunized groups showed increased body weight gain when compared to the control group, and the P-QR group had significantly higher body weight gain than did those of the P and P-Q groups following EA challenge infection. All groups immunized with profilin showed significantly decreased intestinal lesions compared with the control group, with the P-QR group showing the lowest intestinal lesions among the profilin-treated groups. Finally, the P-QR group showed greater CD4+/CD8+ and TCR1+/TCR2+ splenocytes and higher antiprofilin serum antibody titers compared with the P and P-Q (or both) groups following EA challenge infection. These results further suggest that vaccination of chickens with profilin, in combination with the QCDCRT adjuvant, may provide a novel control strategy against EA infection in commercial flocks.
Collapse
Affiliation(s)
- Sung Hyen Lee
- Animal and Natural Resources Institute, Agricultural Research Service-United States Department of Agriculture, Beltsville, MD 20705, USA
| | | | | | | | | | | | | | | |
Collapse
|
7
|
Zulpo DL, Headley SA, Biazzono L, da Cunha IAL, Igarashi M, de Barros LD, Taroda A, Cardim ST, Bogado ALG, Navarro IT, Garcia JL. Oocyst shedding in cats vaccinated by the nasal and rectal routes with crude rhoptry proteins of Toxoplasma gondii. Exp Parasitol 2012; 131:223-30. [PMID: 22542988 DOI: 10.1016/j.exppara.2012.04.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2011] [Revised: 03/30/2012] [Accepted: 04/09/2012] [Indexed: 10/28/2022]
|
8
|
Kim DK, Lillehoj HS, Lee SH, Dominowski P, Yancey RJ, Lillehoj EP. Effects of novel vaccine/adjuvant complexes on the protective immunity against Eimeria acervulina and transcriptome profiles. Avian Dis 2012; 56:97-109. [PMID: 22545534 DOI: 10.1637/9720-031711-reg.1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
SUMMARY. This study investigated the ability of two novel adjuvant formulations, QCDC (Quil A/cholesterol/DDA/ Carbopol) and QCDCR (QCDC/Bay R1005), in combination with a recombinant profilin vaccine, to modulate host protective immunity and to alter gene expression during experimental avian coccidiosis. Vaccination with profilin plus QCDCR significantly reduced the severity of intestinal lesions and increased mitogen-induced lymphocyte proliferation in infected chickens compared with immunization with profilin alone or profilin plus QCDC. Immunization with profilin plus QCDC or profilin plus QCDCR increased body weight gain but had no effect on fecal oocyst shedding of chickens infected with Eimeria acervulina compared with birds vaccinated with profilin alone. The results of global gene expression analysis revealed that, compared with PBS controls, (a) chickens vaccinated with profilin alone had 71 up-regulated and 56 down-regulated mRNA transcripts, (b) chickens immunized with profilin plus QCDC had 198 up-regulated and 247 down-regulated mRNAs, and (c) birds immunized with profilin plus QCDCR had 210 up-regulated and 267 down-regulated mRNAs. Compared with birds vaccinated with profilin alone, (a) chickens given profilin plus QCDC had 60 up-regulated and 104 down-regulated transcripts and (b) chickens immunized with profilin plus QCDCR had 103 up-regulated and 130 down-regulated mRNAs. Finally, chickens vaccinated with profilin plus QCDCR had 193 up-regulated and 204 down-regulated transcripts compared with birds given profilin plus QCDC. Biological function and network analysis revealed that the majority of altered transcripts were encoded by immune-related genes.
Collapse
Affiliation(s)
- Duk Kyung Kim
- Animal Parasitic Diseases Laboratory, Agricultural Research Service, U.S. Department of Agriculture, Beltsville, MD 20705, USA
| | | | | | | | | | | |
Collapse
|
9
|
Esvaran M, Conway P. Strain dependent protection conferred by Lactobacillus spp. administered orally with a Salmonella Typhimurium vaccine in a murine challenge model. Vaccine 2012; 30:2654-61. [DOI: 10.1016/j.vaccine.2012.02.011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2011] [Revised: 01/30/2012] [Accepted: 02/05/2012] [Indexed: 12/27/2022]
|
10
|
da Cunha IAL, Zulpo DL, Bogado ALG, de Barros LD, Taroda A, Igarashi M, Navarro IT, Garcia JL. Humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A. Vet Parasitol 2011; 186:216-21. [PMID: 22137347 DOI: 10.1016/j.vetpar.2011.11.034] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2011] [Revised: 11/02/2011] [Accepted: 11/08/2011] [Indexed: 11/25/2022]
Abstract
We evaluated the humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A. The experiment used 13 mixed-breed pigs divided into the following three groups: G1 (vaccinated-challenged, n=6), which received the rhoptry vaccine (200(g/dose); G2 (adjuvant-challenged, n=4), which received PBS plus Quil-A; and G3 (unvaccinated-challenged, n=3), which was the control group. The treatments were performed intranasally at days 0, 21, and 42. Three pigs from G1 produced IgG and IgM antibody levels above the cut-off in the ELISA on the challenge day. Partial protection was observed in G1 at the chronic phase of infection when compared with G3. The preventable fractions were 41.6% and 6.5%, in G1 and G2, respectively. The results of this study suggest that rhoptry proteins plus Quil-A stimulated humoral, local, and systemic immune responses, which were able to partially protect the brain from cyst formation.
Collapse
Affiliation(s)
- Ivo Alexandre Leme da Cunha
- Laboratório de Protozoologia, Departamento de Medicina Veterinária Preventiva, Universidade de Londrina - UEL, Postal Box 6001, 86050-970 Londrina, PR, Brazil
| | | | | | | | | | | | | | | |
Collapse
|
11
|
Igarashi M, Zulpo DL, Cunha IALD, Barros LD, Pereira VF, Taroda A, Navarro IT, Vidotto O, Vidotto MC, Jenkins MC, Garcia JL. Toxoplasma gondii: humoral and cellular immune response of BALB/c mice immunized via intranasal route with rTgROP2. ACTA ACUST UNITED AC 2011; 19:210-6. [PMID: 21184696 DOI: 10.1590/s1984-29612010000400004] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2010] [Accepted: 11/05/2010] [Indexed: 11/22/2022]
Abstract
TgROP2 is an intracellular protein associated with rhoptries of Toxoplama gondii and an antigen component of a candidate vaccine for toxoplasmosis. The purpose of the present study was to evaluate the efficacy of rTgROP2 to stimulate humoral and cellular immune responses in BALB/c mice via intranasal injection. TgROP2 partial coding sequence was (196-561) amplified by PCR from genomic T. gondii RH strain DNA and cloned into the pTrcHis expression vector. Escherichia coli Rosetta 2 cells transformed with pTrcHis-TgROP2 showed high levels (~1 mg.mL(-1)) of recombinant protein after 4 hours of IPTG induction. Recombinant TgROP2 exhibited an apparent Mr equal to 54 kDa. In order to test immunogenicity of the recombinant protein, 10 BALB/c mice received 10 µg of rROP2 protein + 10 µg of Quil-A via intranasal injection. Doses were administered at days 0, 21, and 42. Three animals were euthanized and used to evaluate cellular immune response on day 62. Five (50%) and two (20%) out of ten animals produced IgG (DO mean = 0.307; cut-off = 0.240) and IgA (DO mean = 0.133, cut-off = 0.101), respectively, by ELISA on day 62. The proliferation of splenocytes revealed high stimulation index (SI) when co-cultured with 5, 10 and 15 µg.mL(-1) of rTgROP2. These results indicate that intranasal immunization with recombinant protein ROP2 plus Quil-A can elicit both cellular and humoral immune responses in BALB/c mice.
Collapse
Affiliation(s)
- Michelle Igarashi
- Laboratório de Protozoologia, Departamento de Medicina Veterinária Preventiva, Universidade de Londrina, Londrina-PR, Brazil
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Pandey RS, Dixit VK. Evaluation of ISCOM vaccines for mucosal immunization against hepatitis B. J Drug Target 2010; 18:282-91. [PMID: 19958131 DOI: 10.3109/10611860903450015] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Immune stimulating complexes (ISCOMs) incorporating recombinant hepatitis B surface antigen (HBsAg) was prepared for induction of humoral, cellular and mucosal immunity by intranasal administration. Prepared ISCOMs were characterized for its size, shape, incorporation efficiency, zeta potential, and antigen integrity. Designed ISCOMs possessed negative zeta potential (-21.7 mV) and an average size of 44.1 nm with antigen incorporation efficiency approximately 39 %. Serum anti-HBsAg IgG titer after three high nasal doses of ISCOMs was comparable with titer recorded after alum-HBsAg administered subcutaneously. Similarly, modest but higher cellular response (cytokines level in spleen homogenates) and significantly higher secretory sIgA response in mucosal secretions was observed (P < 0.001) in case of HBsAg ISCOM vaccines. Whereas, alum-HBsAg vaccine did not elicit considerable cellular or mucosal response. Thus, ISCOMs produced humoral, mucosal, and cellular immune responses upon nasal administration although high and multidose administrations were required to elicit potent immune responses. These data demonstrate potential of ISCOMs in their use as a carrier adjuvant for nasal subunit vaccines against hepatitis B.
Collapse
Affiliation(s)
- R S Pandey
- Department of Pharmaceutical Sciences, Dr. Hari Singh Gour Vishwavidyalaya, Sagar - 470 003, Madhya Pradesh, India
| | | |
Collapse
|
13
|
Abstract
Vaccination is an important tool for handling healthcare programs both in developed and developing countries. The current global scenario calls for a more-efficacious, acceptable, cost-effective and reliable method of immunization for many fatal diseases. It is hoped that the adoption of oral vaccines will help to provide an effective vaccination strategy, especially in developing countries. Mucosal immunity generated by oral vaccines can serve as a strong first line of defense against most of the pathogens infecting through the mucosal lining. Advances in elucidating the mechanism of action of oral vaccines will facilitate the design of more effective, new generation vaccines. There are promising developments in the use of different agents to effectively deliver the vaccine candidate. It is hoped that ongoing research may be able to set another cardinal point, after polio vaccine, in eradicating infectious diseases.
Collapse
Affiliation(s)
- Mohd Azhar Aziz
- Department of Radiation Oncology, Case Western Reserve University, Cleveland, OH, USA
| | | | | | | |
Collapse
|
14
|
Aguila A, Donachie AM, Peyre M, McSharry CP, Sesardic D, Mowat AM. Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine. Vaccine 2006; 24:5201-10. [PMID: 16650917 DOI: 10.1016/j.vaccine.2006.03.081] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2005] [Revised: 03/21/2006] [Accepted: 03/27/2006] [Indexed: 11/30/2022]
Abstract
There is increasing concern over the efficacy of existing vaccines for diphtheria and there is interest in the development of a mucosally active formulation which might improve local protection. Lipophilic immune stimulating complexes (ISCOMS) containing Quil A are active by both parenteral and mucosal routes and here we have established methods for incorporating palmitified diphtheria toxoid (DT) into ISCOMS. The resulting formulation was immunogenic by the subcutaneous, oral and intranasal routes, with very low doses of DT inducing systemic humoral immune responses, as well as cell mediated immunity including both gammaIFN and IL5 production. Intranasal immunisation with DT in ISCOMS also stimulated significant local antibody production in tracheal washes, as well as cellular immunity in draining lymphoid tissues and serum neutralising antibodies. Finally, subcutaneous immunisation of guinea pigs with DT in ISCOMS primed protective immunity against challenge with diphtheria holotoxin more efficiently than the equivalent doses of DT in the conventional alum vaccine. ISCOMS based vaccines may provide a novel strategy for mucosal and systemic immunisation against diphtheria.
Collapse
Affiliation(s)
- Antonio Aguila
- Division of Immunology, Infection and Inflammation, University of Glasgow, Biomedical Research Centre, 120 University Place, Glasgow, Scotland G12 8TA, United Kingdom
| | | | | | | | | | | |
Collapse
|
15
|
Helgeby A, Robson NC, Donachie AM, Beackock-Sharp H, Lövgren K, Schön K, Mowat A, Lycke NY. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. THE JOURNAL OF IMMUNOLOGY 2006; 176:3697-706. [PMID: 16517738 DOI: 10.4049/jimmunol.176.6.3697] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
The cholera toxin A1 (CTA1)-DD/QuilA-containing, immune-stimulating complex (ISCOM) vector is a rationally designed mucosal adjuvant that greatly potentiates humoral and cellular immune responses. It was developed to incorporate the distinctive properties of either adjuvant alone in a combination that exerted additive enhancing effects on mucosal immune responses. In this study we demonstrate that CTA1-DD and an unrelated Ag can be incorporated together into the ISCOM, resulting in greatly augmented immunogenicity of the Ag. To demonstrate its relevance for protection against infectious diseases, we tested the vector incorporating PR8 Ag from the influenza virus. After intranasal immunization we found that the immunogenicity of the PR8 proteins were significantly augmented by a mechanism that was enzyme dependent, because the presence of the enzymatically inactive CTA1R7K-DD mutant largely failed to enhance the response over that seen with ISCOMs alone. The combined vector was a highly effective enhancer of a broad range of immune responses, including specific serum Abs and balanced Th1 and Th2 CD4(+) T cell priming as well as a strong mucosal IgA response. Unlike unmodified ISCOMs, Ag incorporated into the combined vector could be presented by B cells in vitro and in vivo as well as by dendritic cells; it also accumulated in B cell follicles of draining lymph nodes when given s.c. and stimulated much enhanced germinal center reactions. Strikingly, the enhanced adjuvant activity of the combined vector was absent in B cell-deficient mice, supporting the idea that B cells are important for the adjuvant effects of the combined CTA1-DD/ISCOM vector.
Collapse
Affiliation(s)
- Anja Helgeby
- Department of Clinical Immunology, University of Goteborg, 413 46 Goteborg, Sweden
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Recently, the first use of bacterial spores as vaccine vehicles was reported, showing that mice orally immunised with Bacillus subtilis spores expressing a tetanus antigen could be protected against lethal challenge with tetanus toxin. Unlike many second generation vaccine systems currently under development, none offer the heat stability of bacterial spores or the flexibility for genetic manipulation. The current use of Bacillus spores as probiotics for both humans and animals may facilitate their eventual licensing as oral vaccines. This review reports the progress that has been made in the establishment of bacterial spores as vaccine vehicles and outlines the potential advantages of the spore vaccine approach.
Collapse
Affiliation(s)
- Le H Duc
- School of Biological Sciences, Royal Holloway, University of London, Egham, Surrey, TW20 0EX, UK
| | | |
Collapse
|
17
|
Meyer JP, Gillatt DA. PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis 2004; 5:13-5. [PMID: 15195124 DOI: 10.1038/sj.pcan.4500563] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2001] [Revised: 10/20/2001] [Accepted: 11/22/2001] [Indexed: 11/09/2022]
Abstract
In this review the authors consider the commercially available herbal product PC-SPES. This is a combination of eight different herbs marketed for its effects of reducing prostate specific antigen (PSA) levels, improving pain, and enhancing the quality of life of those with hormone refractory prostate cancer. The evidence for these claims does not appear to be as conclusive as reported by the manufactures of this product. There also appears to be a significant risk of deep vein thrombosis (DVT) in those treated with PC-SPES. There have been 116 clinical and laboratory based studies of PC-SPES published to date, but there have been no randomised controlled trials conducted. Many of these studies contain very few patients, thus making the drawing of conclusions difficult. Despite this lack of information, there still remains a large patient group taking this supplement, therefore caution should be advised in the usage of PC-SPES in the treatment of hormone refractory prostate cancer.
Collapse
Affiliation(s)
- J-P Meyer
- Bristol Urological Institute, Southmead Hospital, Westbury-on-Trym, Bristol, UK.
| | | |
Collapse
|
18
|
Abstract
Mucosally active vaccine adjuvants which will prime a full range of local and systemic immune responses against defined antigenic epitopes are much needed. Cholera toxin (CT) and lipophilic immune stimulating complexes (ISCOMs) containing Quil A can both act as adjuvants for orally administered antigens, but through separate pathways, as evidenced by the dependence on IL-12 for the effect of ISCOMs, whereas CT is independent of this cytokine. Unfortunately the toxicity of CT and recent findings of accumulation of CT in the olfactory nerve and bulb after intranasal administration precludes the clinical use of CT. However, we have been successful in separating the adjuvant and toxic effects of CT, by constructing a gene fusion protein, CTA1-DD, that combines the enzymatically active CTA1-subunit with a B cell targeting moiety, D, derived from Staphylococcus aureus protein A. The present review gives a background to mucosal immunization and the use of -adjuvants in general, followed by a description of a strategy to rationally design a vaccine adjuvant vector that fulfils the criteria of targeting and immunomodulating innate immunity in order to boost a strong adaptive immune response. We have combined CTA1-DD and ISCOMs into a new highly promising vaccine adjuvant vector, CTA1-DD/ISCOMs. The combined vector is immunogenic when given by the subcutaneous, oral or nasal routes, inducing strong cell--mediated and humoral immune responses, including local mucosal IgA. It requires the ADP ribosylating property of the CTA1-enzyme and the effect of the combined vector greatly exceeded the effect of either ISCOMs or CT used alone. Antigens could be incorporated into or just admixed with the new vector. Thus, we have demonstrated that rationally designed vectors consisting of CTA1-DD and ISCOMS may provide a novel strategy for the generation of potent and safe mucosal vaccines.
Collapse
Affiliation(s)
- Nils Lycke
- Department of Clinical Immunology, University of Göteborg, S413 46 Göteborg, Sweden.
| |
Collapse
|
19
|
Furrie E, Smith RE, Turner MW, Strobel S, Mowat AM. Induction of local innate immune responses and modulation of antigen uptake as mechanisms underlying the mucosal adjuvant properties of immune stimulating complexes (ISCOMS). Vaccine 2002; 20:2254-62. [PMID: 12009281 DOI: 10.1016/s0264-410x(02)00106-8] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
Lipophilic immune stimulating complexes (ISCOMS) containing the Quil A adjuvant can induce local and systemic immune responses against orally delivered protein antigens. Here, we have examined the possibility that ISCOMS act by modulating local innate immune responses and antigen uptake in the intestine. Feeding ISCOMS to mice induced recruitment of dendritic cells (DCs), activated macrophages (mphi) and lymphocytes into the mesenteric lymph node (MLN), as well as recruitment of macrophages and B cells into the PP. Feeding ISCOMS also enhanced the absorption into circulation of a test feed of ovalbumin (OVA), with accelerated kinetics and increased peak levels. Serum taken 1h after feeding a tolerogenic dose of OVA to mice given ISCOMS orally did not induce the tolerance of systemic delayed type hypersensitivity (DTH) and antibody responses found in mice receiving serum from donors fed OVA alone. Thus, ISCOMS may increase the immunogenicity of intestinal antigen via a combination of effects on antigen uptake and on local accessory cells.
Collapse
|
20
|
Mowat AM, Donachie AM, Jägewall S, Schön K, Löwenadler B, Dalsgaard K, Kaastrup P, Lycke N. CTA1-DD-immune stimulating complexes: a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 2001; 167:3398-405. [PMID: 11544331 DOI: 10.4049/jimmunol.167.6.3398] [Citation(s) in RCA: 51] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Mucosally active vaccine adjuvants that will prime a full range of local and systemic immune responses against defined antigenic epitopes are much needed. Cholera toxin and lipophilic immune stimulating complexes (ISCOMS) containing Quil A can both act as adjuvants for orally administered Ags, possibly by targeting different APCs. Recently, we have been successful in separating the adjuvant and toxic effects of cholera toxin by constructing a gene fusion protein, CTA1-DD, that combines the enzymatically active CTA1-subunit with a B cell-targeting moiety, D, derived from Staphylococcus aureus protein A. Here we have extended this work by combining CTA1-DD with ISCOMS, which normally target dendritic cells and/or macrophages. ISCOMS containing a fusion protein comprising the OVA(323-339) peptide epitope linked to CTA1-DD were highly immunogenic when given in nanogram doses by the s.c., oral, or nasal routes, inducing a wide range of T cell-dependent immune responses. In contrast, ISCOMS containing the enzymatically inactive CTA1-R7K-DD mutant protein were much less effective, indicating that at least part of the activity of the combined vector requires the ADP-ribosylating property of CTA1. No toxicity was observed by any route. To our knowledge, this is the first report on the successful combination of two mechanistically different principles of adjuvant action. We conclude that rationally designed vectors consisting of CTA1-DD and ISCOMS may provide a novel strategy for the generation of potent and safe mucosal vaccines.
Collapse
Affiliation(s)
- A M Mowat
- Department of Immunology and Bacteriology, University of Glasgow, Western Infirmary, Glasgow, Scotland.
| | | | | | | | | | | | | | | |
Collapse
|
21
|
Ryan EJ, Daly LM, Mills KH. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 2001; 19:293-304. [PMID: 11451471 DOI: 10.1016/s0167-7799(01)01670-5] [Citation(s) in RCA: 116] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Current paediatric immunization programmes include too many injections in the first months of life. Oral or nasal vaccine delivery eliminates the requirement for needles and can induce immunity at the site of infection. However, protein antigens are poorly immunogenic when so delivered and can induce tolerance. Novel ways to enhance immune responses to protein or polysaccharide antigens have opened up new possibilities for the design of effective mucosal vaccines. Here, we discuss the immunological principles underlying mucosal vaccine development and review the application of immunomodulatory molecules and delivery systems to the selective enhancement of protective immune responses at mucosal surfaces.
Collapse
Affiliation(s)
- E J Ryan
- Institute of Immunology, National University of Ireland, Maynooth, Co., Kildare, Ireland
| | | | | |
Collapse
|
22
|
Sjölander S, Drane D, Davis R, Beezum L, Pearse M, Cox J. Intranasal immunisation with influenza-ISCOM induces strong mucosal as well as systemic antibody and cytotoxic T-lymphocyte responses. Vaccine 2001; 19:4072-80. [PMID: 11427284 DOI: 10.1016/s0264-410x(01)00110-4] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Intranasal administration of vaccines is preferred for induction of mucosal immune responses. In this study, mice were immunised intranasally and subcutaneously with influenza-immuno stimulating complexes (influenza-ISCOM). The intranasal dose was 15-times the subcutaneous dose. All mice dosed with influenza-ISCOMs survived challenge with live virus and comparable serum antibody and splenic cytotoxic T-lymphocyte responses were detected in both groups. Induction of mucosal IgA was significantly higher with intranasal immunisation and was comparable to responses induced with the heat labile enterotoxin of Escherichia coli as adjuvant. These findings demonstrate that intranasal administration of high dose influenza-ISCOM results in potent systemic and mucosal immune responses.
Collapse
MESH Headings
- Adjuvants, Immunologic/administration & dosage
- Administration, Intranasal
- Animals
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/blood
- Bacterial Toxins/administration & dosage
- Enterotoxins/administration & dosage
- Escherichia coli Proteins
- Humans
- ISCOMs/administration & dosage
- Immunity, Mucosal
- Immunoglobulin A, Secretory/biosynthesis
- Influenza Vaccines/administration & dosage
- Influenza, Human/immunology
- Influenza, Human/prevention & control
- Injections, Subcutaneous
- Mice
- Mice, Inbred BALB C
- Orthomyxoviridae/immunology
- T-Lymphocytes, Cytotoxic/immunology
Collapse
Affiliation(s)
- S Sjölander
- CSL Limited, Immunology Research & Development, Parkville, Vic. 3052, Australia
| | | | | | | | | | | |
Collapse
|
23
|
de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, Burchardt T, Chopin DK, Katz AE. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000; 164:1229-34. [PMID: 10992371 DOI: 10.1097/00005392-200010000-00021] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE We investigate the potential use of the phytotherapeutic PC-SPES to treat human prostate cancer, and evaluate its in vivo and in vitro activity, and clinical efficacy. MATERIALS AND METHODS PC-SPES was evaluated for its ability to induce apoptosis on prostate cancer cell lines LNCaP, PC3 and DU145. The effect of oral PC-SPES on growth of PC3 tumors present in male immunodeficient mice was studied. A total of 30 male nude mice were divided in 5 groups. In groups 1 control and 2 full dose therapy was started the same day of the tumor injection. In groups 3 control, 4 half dose and 5 full dose PC-SPES therapy was initiated 1 week after tumor injection. A total of 69 patients with prostate cancer were treated with 3 capsules of 320 mg. PC-SPES daily. Serum prostate specific antigen (PSA) responses and side effects were evaluated. RESULTS All of the cultured prostate cancer cell lines had a significant dose dependent induction of apoptosis following exposure to an alcoholic PC-SPES extract. Immunodeficient mice xenografted with the PC3 cell line had reduced tumor volume compared with sham treated controls when they were treated with a PC-SPES extract from the time of tumor cell implantation (931 +/- 89 versus 1,424 +/- 685 mm.3, p not significant) but not when the treatment was begun 1 week after tumor cell implantation. The testis, prostate, bladder and seminal vesicles of the treated mice were significantly reduced in weight compared with the sham treated animals. Of the patients with prostate cancer 82% had decreased serum PSA 2 months, 78% 6 months and 88% 12 months after treatment with PC-SPES. Side effects in the treated patient population included nipple tenderness in 42% and phlebitis requiring heparinization in 2%. CONCLUSIONS An extract of the phytotherapeutic agent PC-SPES proved to be active in inducing apoptosis of hormone sensitive and insensitive prostate cancer cells in vitro, and in suppressing the growth rate of a hormone insensitive prostate cancer cell line in vivo. The overwhelming majority of patients with prostate cancer treated with the agent experienced a decrease in serum PSA but also demonstrated a side effect profile comparable to estrogen treatment.
Collapse
Affiliation(s)
- A de la Taille
- Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
24
|
DE LA TAILLE ALEXANDRE, BUTTYAN RALPH, HAYEK OMAR, BAGIELLA EMILIA, SHABSIGH AHMAD, BURCHARDT MARTIN, BURCHARDT TATJANA, CHOPIN DOMINIQUEK, KATZ AARONE. HERBAL THERAPY PC-SPES: IN VITRO EFFECTS AND EVALUATION OF ITS EFFICACY IN 69 PATIENTS WITH PROSTATE CANCER. J Urol 2000. [DOI: 10.1016/s0022-5347(05)67146-7] [Citation(s) in RCA: 43] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Affiliation(s)
- ALEXANDRE DE LA TAILLE
- From the Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, and Department of Urology, Henri Mondor Hospital, Créteil, France
| | - RALPH BUTTYAN
- From the Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, and Department of Urology, Henri Mondor Hospital, Créteil, France
| | - OMAR HAYEK
- From the Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, and Department of Urology, Henri Mondor Hospital, Créteil, France
| | - EMILIA BAGIELLA
- From the Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, and Department of Urology, Henri Mondor Hospital, Créteil, France
| | - AHMAD SHABSIGH
- From the Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, and Department of Urology, Henri Mondor Hospital, Créteil, France
| | - MARTIN BURCHARDT
- From the Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, and Department of Urology, Henri Mondor Hospital, Créteil, France
| | - TATJANA BURCHARDT
- From the Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, and Department of Urology, Henri Mondor Hospital, Créteil, France
| | - DOMINIQUE K. CHOPIN
- From the Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, and Department of Urology, Henri Mondor Hospital, Créteil, France
| | - AARON E. KATZ
- From the Squier Urological Clinic, Department of Urology, Columbia University College of Physicians and Surgeons, Columbia-Presbyterian Medical Center and Department of Biostatistic, Columbia University, School of Public Health, New York, New York, and Department of Urology, Henri Mondor Hospital, Créteil, France
| |
Collapse
|
25
|
Cárdenas-Freytag L, Cheng E, Mirza A. New approaches to mucosal immunization. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2000; 473:319-37. [PMID: 10659373 DOI: 10.1007/978-1-4615-4143-1_34] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Every year more than 17 million deaths worldwide are caused by infectious diseases. The great majority of these deaths occur in underdeveloped countries and are attributed to diseases preventable by existing vaccines, or diseases that could potentially be prevented with new vaccines. The fact that most human and veterinary pathogens establish infection in the host by initiating contact at a mucosal surface, provide the rationale for the development of mucosal vaccines. An increasing number of strategies have been proposed to facilitate mucosal immunization. Among the most widely investigated strategies are the use of attenuated microorganisms; the inclusion of immunizing antigens in lipid-based carriers, the genetic creation of transgenic plants and the use of mucosal adjuvants derived from bacterial toxins. This review provides a brief summary of the most recent advances in the field of mucosal immunization with an special emphasis on a promising genetically detoxified mucosal adjuvant, LT(R192G), derived from the heat-labile toxin of enterotoxigenic E. coli. We present evidence regarding the safety, immunogenicity, and efficacy of LT(R192G) for the development of a new generation of mucosal vaccines.
Collapse
Affiliation(s)
- L Cárdenas-Freytag
- Tulane University School of Medicine, Department of Microbiology and Immunology, New Orleans, Louisiana 70112-2699, USA
| | | | | |
Collapse
|
26
|
Medina E, Guzmán CA. Modulation of immune responses following antigen administration by mucosal route. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY 2000; 27:305-11. [PMID: 10727886 DOI: 10.1111/j.1574-695x.2000.tb01444.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Most microbial infections are either restricted to the mucosal membranes or the etiologic agents needed to transit the mucosa. Thus, it is desirable to stimulate a mucosal response following vaccination, to block both infection and disease development. Attenuated vaccine carriers mimic natural infections, triggering also mucosal responses. Similar results can be achieved by administering antigens with appropriate adjuvants. However, the delivery of antigens per se is not sufficient to engender a protective response. A successful immunization requires the elicitation of an appropriate type of immune response (e.g. antibodies vs. cell-mediated immunity, Th1 vs. Th2 helper pattern). Therefore, a successful vaccination strategy demands the choice of adequate antigens, and their appropriate delivery and/or formulation to promote the required quality of immune response. Different strategies to optimize the immune responses elicited following vaccine administration by the mucosal route are discussed.
Collapse
Affiliation(s)
- E Medina
- Department of Microbial Pathogenesis and Vaccine Research, Division of Microbiology, GBF-German Research Centre for Biotechnology, Mascheroder Weg 1, D-38124, Braunschweig, Germany
| | | |
Collapse
|
27
|
van Pinxteren LA, Bruce MG, Campbell I, Wood A, Clarke CJ, Bellman A, Morein B, Snodgrass DR. Effect of oral rotavirus/iscom vaccines on immune responses in gnotobiotic lambs. Vet Immunol Immunopathol 1999; 71:53-67. [PMID: 10522786 DOI: 10.1016/s0165-2427(99)00087-2] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A comparison of the effect on the immune responses in gnotobiotic lambs was made between an iscom vaccine prepared from recombinant rotavirus VP6 protein, an inactivated rotavirus/iscom-matrix vaccine and a vaccine comprising inactivated rotavirus alone. All three vaccines induced immunological priming and some degree of protection was observed after a single oral dose. However, different immune responses were induced in response to a virulent infection. The group vaccinated with the rotavirus/iscom-matrix vaccine showed a Th2-like response characterised by rotavirus-specific antibodies and a down-regulation of IFNgamma in jejunal Peyer's patches. Both Th1-like and Th2-like immune responses were induced in the group receiving the VP6 vaccine as seen by significantly increased expressions of IFNgamma and IL-6 in the jejunal Peyer's patch together with an increased percentage of CD8+ T cells in the intestine and rotavirus-specific antibodies at mucosal surfaces. Iscom vaccines given orally have the ability to induce both Th1-like and Th2-like immune responses in a ruminant model.
Collapse
Affiliation(s)
- L A van Pinxteren
- Moredun Research Institute, International Research Centre, Pentlands Science Park, Penicuik, Midlothian, UK.
| | | | | | | | | | | | | | | |
Collapse
|
28
|
Smith RE, Donachie AM, Grdic D, Lycke N, Mowat AM. Immune-Stimulating Complexes Induce an IL-12-Dependent Cascade of Innate Immune Responses. THE JOURNAL OF IMMUNOLOGY 1999. [DOI: 10.4049/jimmunol.162.9.5536] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Abstract
The development of subunit vaccines requires the use of adjuvants that act by stimulating components of the innate immune response. Immune-stimulating complexes (ISCOMS) containing the saponin adjuvant Quil A are potential vaccine vectors that induce a wide range of Ag-specific responses in vivo encompassing both humoral and CD4 and CD8 cell-mediated immune responses. ISCOMS are active by both parenteral and mucosal routes, but the basis for their adjuvant properties is unknown. Here we have investigated the ability of ISCOMS to recruit and activate innate immune responses as measured in peritoneal exudate cells. The i.p. injection of ISCOMS induced intense local inflammation, with early recruitment of neutrophils and mast cells followed by macrophages, dendritic cells, and lymphocytes. Many of the recruited cells had phenotypic evidence of activation and secreted a number of inflammatory mediators, including nitric oxide, reactive oxygen intermediates, IL-1, IL-6, IL-12, and IFN-γ. Of the factors that we investigated further only IL-12 appeared to be essential for the immunogenicity of ISCOMS, as IL-6- and inducible nitric oxide synthase knockout (KO) mice developed normal immune responses to OVA in ISCOMS, whereas these responses were markedly reduced in IL-12KO mice. The recruitment of peritoneal exudate cells following an injection of ISCOMS was impaired in IL-12KO mice, indicating a role for IL-12 in establishing the proinflammatory cascade. Thus, ISCOMS prime Ag-specific immune responses at least in part by activating IL-12-dependent aspects of the innate immune system.
Collapse
Affiliation(s)
- Rosemary E. Smith
- *Department of Immunology, University of Glasgow, Western Infirmary, Glasgow, United Kingdom; and
| | - Anne M. Donachie
- *Department of Immunology, University of Glasgow, Western Infirmary, Glasgow, United Kingdom; and
| | - Dubravka Grdic
- †Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
| | - Nils Lycke
- †Department of Microbiology and Immunology, University of Gothenburg, Gothenburg, Sweden
| | - Allan McI. Mowat
- *Department of Immunology, University of Glasgow, Western Infirmary, Glasgow, United Kingdom; and
| |
Collapse
|